journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/28430756/does-pregnancy-influence-melanoma-prognosis-a-meta-analysis
#1
Athanassios Kyrgidis, Aimilios Lallas, Elvira Moscarella, Caterina Longo, Roberto Alfano, Giuseppe Argenziano
The literature has not been able to conclude whether pregnancy influences the prognosis of melanoma. The aim of this study was to explore the prognosis of melanoma diagnosed during pregnancy or post partum [pregnancy-associated melanoma (PAM)] compared with melanoma in female patients who were not pregnant. We systematically searched for studies of female patients with melanoma that reported outcomes related to survival. Fifteen eligible studies were found. Overall, PAM was associated with a 17% higher mortality compared with melanoma diagnosed in female patients who were not pregnant (hazard ratio=1...
April 20, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28419059/late-onset-nivolumab-mediated-pneumonitis-in-a-patient-with-melanoma-and-multiple-immune-related-adverse-events
#2
Panagiotis T Diamantopoulos, Maria Gaggadi, Eva Kassi, Olga Benopoulou, Amalia Anastasopoulou, Helen Gogas
Immune-related adverse effects (AEs) of PD-1 inhibitors can affect almost every organ, but the skin, intestine, lung, eye, and liver are the most commonly affected organs. Here, we present the case of a 62-year-old female patient with stage IIIc melanoma treated with nivolumab in an adjuvant setting who sequentially developed hyperthyroidism, hypothyroidism, acute hepatitis, and pneumonitis. Six months before the emergence of pneumonitis, the patient had discontinued treatment with nivolumab because of acute hepatitis...
April 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28410287/critical-points-of-t1-stage-in-primary-melanoma
#3
Francesco Piscioli, Teresa Pusiol, Luca Roncati
No abstract text is available yet for this article.
April 13, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28410286/successful-treatment-with-imatinib-after-nilotinib-and-ipilimumab-in-a-c-kit-mutated-advanced-melanoma-patient-a-case-report
#4
Carla Murer, Pascale Kränzlin-Stieger, Lars E French, Reinhard Dummer, Simone M Goldinger
Treatment of melanoma remains a challenge in advanced disease. Recently, the molecular differentiation in BRAF-mutated, NRAS-mutated and c-kit-mutated melanomas led to new treatment strategies. Different trials show that imatinib or nilotinib lead to meaningful responses in c-kit-mutated melanoma patients. There are little published data on sequential inhibition using these two drugs in melanoma. We describe the sequential use of imatinib after nilotinib in a c-kit-mutated melanoma patient, who progressed on interferon, Allovectin, dacarbazine, nilotinib and ipilimumab, and was finally treated with the c-kit inhibitor imatinib...
April 13, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28296712/association-between-the-use-of-surveillance-pet-ct-and-the-detection-of-potentially-salvageable-occult-recurrences-among-patients-with-resected-high-risk-melanoma
#5
Roberto A Leon-Ferre, Lisa A Kottschade, Matthew S Block, Robert R McWilliams, Roxana S Dronca, Edward T Creagan, Jacob B Allred, Val J Lowe, Svetomir N Markovic
The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III-IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota)...
March 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28296711/prognostic-role-of-the-histological-subtype-of-melanoma-on-the-hands-and-feet-in-caucasians
#6
Cristina Carrera, Adrià Gual, Alba Díaz, Joan A Puig-Butillé, Susanna Noguès, Antonio Vilalta, Carlos Conill, Ramón Rull, Ramon Vilana, Pedro Arguis, Sergi Vidal-Sicart, Llucia Alós, Josep Palou, Teresa Castel, Josep Malvehy, Susana Puig
Acral melanoma (AM) is associated with a poor prognosis in part because of delayed diagnosis, but probably also because of other intrinsic characteristics of location. The aim of this study was to review the specific characteristics and outcome of AM in Caucasians. This was a cross-sectional retrospective clinical-pathological study of 274 patients identified with AM in the database of a referral unit in Europe from 1986 to 2010. The mean age of the patients was 56.6 (SD 17.7) years. 269 cases could be histologically classified and included in the study...
March 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28263240/peptide-pulsed-dendritic-cell-vaccine-in-combination-with-carboplatin-and-paclitaxel-chemotherapy-for-stage-iv-melanoma
#7
Keitaro Fukuda, Takeru Funakoshi, Toshiharu Sakurai, Yoshio Nakamura, Mariko Mori, Keiji Tanese, Akiko Tanikawa, Junichi Taguchi, Tomonobu Fujita, Masato Okamoto, Masayuki Amagai, Yutaka Kawakami
In this study, we aimed to evaluate the feasibility and efficacy of peptide-pulsed dendritic cell (DC) vaccine in combination with carboplatin and paclitaxel chemotherapy (DCCP) for patients with stage IV melanoma previously treated with dacarbazine-containing regimen. Six HLA-A24 and 3 HLA-A02 patients were treated with carboplatin (area under the curve 5) and paclitaxel (175 mg/m) on day 1 and DCs (2×10 cells) pulsed with Wilms tumor gene 1 (WT1), gp100, tyrosinase, and either MAGE-A3 (for HLA-A24) or MAGE-A2 (for HLA-A02) peptides on days 8 and 22 in 28-day cycle for up to three cycles...
March 3, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28257394/reinduction-of-pd1-inhibitor-therapy-first-experience-in-eight-patients-with-metastatic-melanoma
#8
Hanna Blasig, Carolin Bender, Jessica C Hassel, Thomas K Eigentler, Michael M Sachse, Julia Hiernickel, Anika Koop, Imke Satzger, Ralf Gutzmer
Significant progress has been made in the treatment of metastatic melanoma during the last years. Approval of immune-checkpoint inhibitors and targeted therapies has been achieved recently. The sequencing of these therapies is an important issue. Here, we report our experience with the treatment and retreatment with PD1-inhibitors (PD1i) in eight patients. The patients (two female and seven male with a median age of 70 years, all melanoma stage IV, M1c) underwent a first treatment period with PD1i for a median of 5...
March 2, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28234768/scalp-melanoma-is-associated-with-high-mitotic-rate-and-is-a-poor-prognostic-factor-for-recurrence-and-outcome
#9
Faruk Tas, Kayhan Erturk
A small subset of head and neck melanoma, scalp melanoma comprises 3-5% of all cutaneous melanomas. So far, small numbers of researches on scalp melanoma have yielded controversial results. In this trial, we aimed to define the histopathological and clinical features specific to scalp melanoma and to compare them with melanomas that occurred on other sites by using a large group of patients from a single institution. The data of 93 patients with scalp melanoma and 1076 patients with melanomas on other sites were analyzed retrospectively...
February 23, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099367/antiphospholipid-syndrome-associated-with-combined-immune-checkpoint-inhibitor-therapy
#10
Arjun Gupta, Udayan Shah, Htet Khine, Travis Vandergriff, Thomas Froehlich
No abstract text is available yet for this article.
January 31, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28346289/%C3%AE-blocker-use-and-reduced-disease-progression-in-patients-with-thick-melanoma-8-years-of-follow-up
#11
Vincenzo De Giorgi, Marta Grazzini, Silvia Benemei, Niccolò Marchionni, Pierangelo Geppetti, Sara Gandini
Previous observational studies have reported the protective effect of β-blockers on the progression of different types of cancers. In 2011, we published a prospective study, including patients with histologically confirmed malignant melanoma in stage II-IIIA. In total, 25% of them reported previous use of β-blockers that were administered at any time for any other diseases. After a median follow-up of 2.5 years, 34% of the patients in the untreated group showed disease progression. In contrast, only 3% of the patients in the treated group showed progression...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28296713/whole-exome-sequencing-identifies-recurrent-sf3b1-r625-mutation-and-comutation-of-nf1-and-kit-in-mucosal-melanoma
#12
Jennifer D Hintzsche, Nicholas T Gorden, Carol M Amato, Jihye Kim, Kelsey E Wuensch, Steven E Robinson, Allison J Applegate, Kasey L Couts, Theresa M Medina, Keith R Wells, Joshua A Wisell, Martin D McCarter, Neil F Box, Yiqun G Shellman, Rene C Gonzalez, Karl D Lewis, John J Tentler, Aik Choon Tan, William A Robinson
Mucosal melanomas are a rare subtype of melanoma, arising in mucosal tissues, which have a very poor prognosis due to the lack of effective targeted therapies. This study aimed to better understand the molecular landscape of these cancers and find potential new therapeutic targets. Whole-exome sequencing was performed on mucosal melanomas from 19 patients and 135 sun-exposed cutaneous melanomas, with matched peripheral blood samples when available. Mutational profiles were compared between mucosal subgroups and sun-exposed cutaneous melanomas...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28272106/m1-and-m2-macrophages-clinicopathological-significance-in-cutaneous-melanoma
#13
Monica Falleni, Federica Savi, Delfina Tosi, Elena Agape, Amilcare Cerri, Laura Moneghini, Gaetano P Bulfamante
Skin malignant melanoma (MM) is an aggressive cancer with an increasing incidence with limited therapies in advanced stages. Tumor-associated macrophages (TAMs) are the major immune constituent of the MM microenvironment and contribute toward its prognosis. TAMs' characterization and localization in human cancer is important to understand cancer progression and to identify molecular personalized therapies. M2 TAMs in stage I-II MMs are associated with worse prognostic parameters. A comprehensive M1-macrophage and M2-macrophage intratumoral localization and quantification in all stages of skin MMs is documented here with its clinical significance...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28252554/clinical-and-dermoscopic-features-of-truly-amelanotic-plantar-melanoma
#14
Vincenzo De Giorgi, Alessia Gori, Imma Savarese, Antonietta D'Errico, Federica Papi, Marta Grazzini, Federica Scarfì, Piero Covarelli, Daniela Massi
Currently, there are no specific clinical and dermoscopic features for diagnosing truly amelanotic plantar melanoma (TAPM). The present study aimed to investigate the dermoscopic features of all clinical variants of TAMPS and to evaluate their histopathological correlations. A retrospective analysis of prospectively collected data was carried out during a 10-year period (2003-2013). We analyzed the clinical data of 1321 patients, who had received a histological diagnosis of melanoma at the Melanoma Unit of the University of Florence...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28252553/interactions-from-complementary-and-alternative-medicine-in-patients-with-melanoma
#15
Carmen Loquai, Irene Schmidtmann, Marlene Garzarolli, Martin Kaatz, Katharina C Kähler, Peter Kurschat, Frank Meiss, Oliver Micke, Ralph Muecke, Karsten Muenstedt, Dorothee Nashan, Annette Stein, Christoph Stoll, Dagmar Dechent, Jutta Huebner
Biological-based (BbCAM) methods from complementary and alternative medicine (CAM) may interact with cancer treatments, reduce efficacy, or enhance adverse effects. Although CAM usage has been evaluated well in other cancer entities, data on melanoma patients are still missing. The aim of this study was to determine CAM usage of melanoma patients using a standardized questionnaire to identify potential interactions with established and new systemic melanoma therapies. This multicenter study was carried out in seven German skin cancer centers...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28240681/braf-inhibitor-discontinuation-and-rechallenge-in-advanced-melanoma-patients-with-a-complete-initial-treatment-response
#16
Céline Desvignes, Henry Abi Rached, Carole Templier, Elodie Drumez, Pauline Lepesant, Eve Desmedt, Laurent Mortier
BRAF inhibitors (BRAFi), a targeted therapy, are used to treat metastatic late-stage melanomas harbouring the BRAF-V600 mutation (found in about 50% of melanomas). The targeted therapy is generally maintained until tumour progression or major toxicity occurs, although responses are often limited in time. It is unknown whether melanoma patients achieving a complete response with targeted therapy can safely discontinue treatment. We retrospectively observed the clinical course of patients with metastatic melanoma who discontinued BRAFi therapy after achieving a complete response and those with an incomplete response combined with surgical removal of the remaining tumours...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28234767/altered-integrin-expression-patterns-shown-by-microarray-in-human-cutaneous-melanoma
#17
Laura Vizkeleti, Timea Kiss, Viktoria Koroknai, Szilvia Ecsedi, Orsolya Papp, Istvan Szasz, Roza Adany, Margit Balazs
A large variety of molecular pathways in melanoma progression suggests that no individual molecular alteration is crucial in itself. Our aim was to define the molecular alterations underlying metastasis formation. Gene expression profiling was performed using microarray and qRT-PCR to define alterations between matched primary and metastatic melanoma cell lines. These data were integrated with publicly available unmatched tissue data. The invasiveness of cell lines was determined by Matrigel invasion assays and invasive clones from primary melanoma-derived cell lines were also selected...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28230715/a-multireferral-centre-retrospective-cohort-analysis-on-the-experience-in-treatment-of-metastatic-uveal-melanoma-and-utilization-of-sequential-liver-directed-treatment-and-immunotherapy
#18
Malinda Itchins, Paolo A Ascierto, Alexander M Menzies, Meredith Oatley, Serigne Lo, Dariush Douraghi-Zadeh, Timmothy Harrington, Richard Maher, Antonio M Grimaldi, Alexander Guminski
Metastatic uveal melanoma is a rare malignancy with a poor prognosis. To date, systemic therapy has been ineffective; however, there are few data on the benefits of anti-CTLA4 or anti-PD-1 antibodies in sequence with liver-directed therapy. A retrospective cohort analysis was carried out on 37 consecutive patients managed in a tertiary referral centre examining the safety and efficacy of treatment; patterns of care; and impact on survival. The sequential treatment with transarterial chemotherapy (TAC), systemic immunotherapy (IT) and systemic chemotherapy was reviewed...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28225434/pet-ct-surveillance-detects-asymptomatic-recurrences-in-stage-iiib-and-iiic-melanoma-patients-a-prospective-cohort-study
#19
Max F Madu, Pieter Timmerman, Michel W J M Wouters, Bernies van der Hiel, Jos A van der Hage, Alexander C J van Akkooi
AJCC stage IIIB and IIIC melanoma patients are at risk for disease relapse or progression. The advent of effective systemic therapies has made curative treatment of progressive disease a possibility. As resection of oligometastatic disease can confer a survival benefit and as immunotherapy is possibly most effective in a low tumor load setting, there is a likely benefit to early detection of progression. The aim of this pilot study was to evaluate a PET/computed tomography (CT) surveillance schedule for resected stage IIIB and IIIC melanoma...
June 2017: Melanoma Research
https://www.readbyqxmd.com/read/28225433/the-role-of-5-hydroxymethylcytosine-in-melanoma
#20
Feng-Juan Li, Li-Ming Li, Rui-Hua Zhang, Cui Xu, Pan Zhou, Jia Long, Gang Hu, Ming-Jun Jiang
Malignant melanoma is a highly aggressive neoplasia of melanocytic origin. In part because of the lack of effective treatment methods, the incidence and mortality rates of this disease continue to increase. Rapidly accumulating evidence suggests that dysregulation of epigenetic mechanisms, including DNA methylation/demethylation, chromatin modification, and remodeling, and diverse activities of noncoding RNAs, play a central role in the pathogenesis of melanoma. The epigenetic mark 5-hydroxymethylcytosine (5-hmC) has attracted interest since 2009, when it was shown that ten-eleven translocation proteins can enzymatically convert 5-methylcytosine into 5-hmC, a key intermediate of DNA demethylation...
June 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"